Define cancer,
one molecule at a time.
Liquid biopsies for advanced cancers with unmatched sensitivity and single-molecule precision.
The most sensitive liquid biopsy for therapy selection.1
Don't miss an opportunity for treatment.
Northstar Select® is the most sensitive liquid biopsy CGP proven to uncover 50%+ more clinically actionable alterations1.
Stay ahead of cancer with real-time molecular insights.
Northstar Response® is the only tissue-free treatment monitoring test that achieves single-molecule precision.
Clarity at every step,
from therapy selection
to response monitoring.
Unprecedented sensitivity, single-molecule quantification, and cancer-specific methylation insights that drive more confident clinical decisions.
Together, Northstar Select and Response bring precision and clarity to the full continuum of care:
Profile
Uncover clinically actionable genomic alterations. This guides personalized therapy decisions from the outset, all without the need for tissue.
Monitor
Track tumor burden dynamically and assess treatment effectiveness earlier than traditional imaging, enabling timely adjustments.
Adapt
Leverage both solutions throughout the treatment journey to make informed, confident decisions — from diagnosis through disease monitoring.
Technology that sees what others miss.
Grounded in rigorous science, with peer-reviewed publications, ongoing clinical research, and a commitment to real-world utility.
Why oncologists trust Northstar:
Quantitative Counting Technology™ (QCT™)
Enables precise, single-molecule measurement of methylated ctDNA molecules. Not just detection, but exact quantification.
Cancer-specific methylation signal
Measures >2200 genomic loci uniquely methylated in cancer cells to assess tumor burden with unmatched sensitivity.
Ultra-sensitive mutation detection
Identifies even low-frequency alterations that may be missed by other tests — expanding the window for action.
Tissue-free, workflow-friendly
All insights come from a simple blood draw. No biopsy required. No added complexity to your practice.
Proven with real-world head-to-head studies and clinical data.
Northstar’s technology is grounded in rigorous science: peer-reviewed publications, ongoing clinical research, and a commitment to real-world utility. While our evidence base is still expanding, our early data speaks volumes.
Powered by BillionToOne
Northstar is part of BillionToOne, a precision diagnostics company unlocking molecular-level insights to improve care for everyone — from prenatal testing to oncology. Together, we’re advancing a new era of accessible, impactful diagnostics.
Based on a head-to-head clinical study [Bower, X., et al., JCO 42, 3072-3072(2024)]
LOD 95% (Limit of Detection 95%) is defined as the lowest concentration of an analyte in a sample that can be consistently detected with ≥95% probability. Comparator assays have a LOD 95% that ranges from 0.20% -0.40%.
Turnaround time is typically within 10 days, from sample receipt to results, internal data on file.
Analytical validation data on file
Based on real-world clinical case studies
